Market Overview

'Overwatch' Could Put Activision Q2 Results Over Street Estimates

Share:
'Overwatch' Could Put Activision Q2 Results Over Street Estimates

Bank of America Merrill Lynch raised its estimates on Activision Blizzard, Inc. (NASDAQ: ATVI) for "Overwatch" in its report released Monday.

The analysts lifted their price target to $44 based on 20x their higher CY17 EPS. The multiple used is "in line with Electronic Arts Inc. (NASDAQ: EA) despite lower net cash."

Related Link: Barron's Picks And Pans: Pharmacy-Benefit Managers, Mortgage Insurers And More

This move was driven by raised estimates on strong performance of Activision's "Overwatch" title, currently estimated to sell 11.6 million units in CY16.

The analysts maintain their Neutral rating, stating, "Overwatch a strong new franchise, but still see more holiday upside for EA's Battlefield."

Full ratings data available on Benzinga Pro.

Did you like this article? Could it have been improved? Please email feedback@benzinga.com with the story link to let us know!

Latest Ratings for ATVI

DateFirmActionFromTo
Jul 2019MaintainsOverweight
Jul 2019Initiates Coverage OnBuy
Jun 2019Initiates Coverage OnNeutral

View More Analyst Ratings for ATVI
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Reiteration Topics Analyst Ratings Tech General

 

Related Articles (ATVI + EA)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
EGBNDowngrades
EBAYMaintains37.0
EBAYMaintains40.0
SQAssumes78.0
PYPLAssumes140.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

AbbVie And Bristol-Myers Squibb Strike Oncology Clinical Alliance To Assess Rova-T plus Opdivo And Opdivo + Yervoy Regimen

Notable Stocks Trading Ex-Dividend Tuesday, July 26